What Are Peptides in Lash Serums?
Plain answer: Peptides are short chains made from amino acids. Lash serums use many kinds. They may help coat or care for lashes. Small human studies have tested blends with peptides. Those studies do not prove that every peptide grows lashes. Each peptide and each full serum need their own proof.
Review status: This is a source-checked editorial draft. Qualified review required before indexation. An ophthalmologist or optometrist must review ocular and drug claims. A dermatologist or cosmetic toxicology expert must review claims within their scope.
Quick facts
| Ingredient class | Short amino-acid chains with different structures and intended cosmetic functions. |
|---|---|
| Common label examples | Myristoyl Pentapeptide-17, Biotinoyl Tripeptide-1, Acetyl Tetrapeptide-3, Copper Tripeptide-1, and other named peptides. |
| Best available human evidence | Small studies of finished, multi-ingredient formulas. |
| Effectiveness evidence grade | C for the exact open-label formulas studied; often E for a claim that one peptide caused growth. |
| Safety position | A 2025 Danish report found no health concern for three exact peptides under surveyed use conditions. That does not clear every peptide or formula. |
| Source check | 2026-07-11 |
Do peptide lash serums work?
Some small human studies report improvements after people used multi-ingredient peptide formulas. That is promising formula-level evidence. It is not proof that all peptide serums work, that one peptide caused the change, or that a peptide formula matches prescription bimatoprost.
A 2024 open-label trial followed 30 women using a peptide and glycosaminoglycan eyelash formula. At 12 weeks, the study reported changes in length, number, width, volume, arc, and angle from baseline. There was no blinded vehicle-control group. Two authors were affiliated with the company that funded the study.
A separate 2020 open-label study tested a polygrowth-factor serum in 30 women, with 29 completing 90 days. SkinGen International funded the work through an educational grant. The product contained several growth factors, oils, peptides, and other ingredients, so its results cannot isolate a peptide.
Effectiveness evidence
The Lash List editorial grade key: A = strong controlled human evidence for the exact use. B = one controlled human study. C = a small uncontrolled human formula study. D = laboratory, animal, scalp-hair, or supplier evidence. E = label presence, theory, or no direct human eyelash evidence. This is our editorial rubric, not a recognized clinical grading system. Grades do not rate safety.
| Evidence type | Evidence grade | Allowed wording |
|---|---|---|
| Independent controlled human eyelash study of an exact peptide | B if one exists | Name the peptide, dose, population, duration, comparator, and measured outcome. |
| Open-label human study of an exact multi-ingredient formula | C | The formula showed changes in that study. Do not assign the result to one peptide. |
| Supplier, laboratory, ex vivo, animal, or sponsored mechanistic work | D | Early or mechanistic evidence only. |
| Brand description, ingredient database, or mechanism theory | E | Not proof of human eyelash growth. |
Safety assessment
| Assessment status | Not assessed as one class. A 2025 Danish EPA project assessed Myristoyl Pentapeptide-17, Biotinoyl Tripeptide-1, and Acetyl Tetrapeptide-3 under stated exposure conditions and found no health concern. |
|---|---|
| Authority | Danish EPA-commissioned survey and risk assessment; peer-reviewed studies of named finished formulas. |
| Scope | The three exact peptides measured in 19 products bought in Denmark and the EU, plus exact formulas and study conditions. The highest measured level of any of the three was about 0.006%. |
| Jurisdiction | Danish and EU market survey context. No global peptide-class or formula-wide conclusion is claimed. |
| Known effects | The Danish report found no direct toxicology data for the three peptides. It assessed their building blocks, could not identify a critical effect or a point of departure for quantitative risk assessment, and concluded no health concern under surveyed use. Two people in the 2020 formula study had brief mild stinging. The 2024 open-label formula paper reported no adverse events. |
| Data gaps | The Danish report found no direct toxicology data for the three peptides. Relevant local eye and skin tests, other peptides and concentrations, full-formula effects, long-term exposure, pregnancy, and nursing remain bounded or unassessed. |
| Checked date | 2026-07-11 |
What did the Danish EPA report find?
The 2025 project surveyed 44 prostaglandin-free lash or brow serums. It measured three common peptides in 19 products. The highest measured level of any one of those peptides was about 0.006%. The report found no health concern for those three peptides under its exposure assumptions.
The limit matters. The report found no direct toxicology data for the three peptide ingredients. It used data about their building blocks and listed missing local tests. It did not assess every peptide, every formula ingredient, every concentration, or products bought outside Denmark and the EU.
Why peptide names cannot be grouped as one active
A peptide is a chemical category, not one ingredient. Myristoyl Pentapeptide-17 is different from Biotinoyl Tripeptide-1 or Copper Tripeptide-1. The name, sequence, concentration, delivery system, and other formula ingredients can change what a peptide does.
A page that says peptides grow lashes skips those differences. Better wording identifies the exact peptide and labels whether the evidence comes from human eyelashes, scalp hair, a finished formula, a laboratory model, or a supplier.
What did the 2024 comprehensive review conclude?
The review found strong support for bimatoprost. It described non-prostaglandin ingredients as promising but said more studies were needed because formal evidence for eyelash-serum use was limited. That supports continued research, not a claim that peptide formulas are equivalent to bimatoprost.
How to read a peptide ingredient list
- Write down the exact peptide name and number.
- Check whether a study tested that peptide or only a finished formula containing it.
- Do not infer a useful concentration from the ingredient's position on the label.
- Separate lash conditioning and reduced breakage from new follicle growth.
- Recheck the current package because formulas can change by date and country.
Which peptide should we cover next?
Myristoyl Pentapeptide-17 has enough search demand for a dedicated evidence page, but its direct ingredient-specific human eyelash evidence is limited. Biotinoyl Tripeptide-1 and Acetyl Tetrapeptide-3 should receive separate pages only after their source records can support more than supplier or scalp-hair claims.
Sources and evidence limits
- 2024 comprehensive review of eyelash serums.
- 2025 Danish EPA survey and risk assessment of eyelash and eyebrow serums.
- 2024 open clinical trial of a peptide and glycosaminoglycan formula.
- 2020 open-label polygrowth-factor serum study.
- 2024 finished-formula eye-area cosmetic study.
Current product label examples
The current official U.S. labels for SOWN Root 1 and The Ordinary Multi-Peptide Lash and Brow Serum list several peptides. Vegamour's current GRO Lash Serum label lists Acetyl Tetrapeptide-3. These matches show label presence, not which ingredient caused a result. Sources checked July 11, 2026; formulas can change.
Related ingredient pages
Use the evidence system
Return to the lash serum ingredient hub, paste a current ingredient label into the checker, or read the ingredient risk guide.
This page is educational. It does not diagnose an eye condition or replace advice from a qualified clinician.